文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

骨髓纤维化患者接受单倍体移植联合移植后环磷酰胺的多中心研究

Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study.
PubMed 文献 · Leukemia · 2021-10-18

这项多中心回顾性研究纳入69例慢性期骨髓纤维化成人患者,接受单倍体血液或骨髓移植联合移植后环磷酰胺。中位年龄63岁,中位随访23.1个月。3年总生存率72%,无复发生存率44%,无GVHD无复发生存率30%。脾大≥22cm或既往脾切除及骨髓移植物与复发增加相关。

要点

  • 单倍体移植联合PTCy在骨髓纤维化中可行,3年总生存率72%。
  • 脾大≥22cm或既往脾切除者复发风险显著增加(HR 6.37)。
  • 骨髓移植物较外周血移植物复发风险更高(HR 4.92)。

核心结论

  • 单倍体血液或骨髓移植联合移植后环磷酰胺在骨髓纤维化患者中可行。
  • 脾大≥22cm和骨髓移植物与更高的复发发生率相关。

研究设计与样本

  • 多中心回顾性研究,纳入69例接受单倍体移植联合PTCy的慢性期骨髓纤维化成人患者。
  • 中位年龄63岁(范围41-74),预处理方案为减低强度54%、非清髓39%,外周血移植物86%。
  • 中位随访23.1个月(范围1.6-75.7)。

主要发现

  • 3年总生存率72%(95%CI 59-81),无复发生存率44%(95%CI 29-59),无GVHD无复发生存率30%(95%CI 17-43)。
  • 3年非复发死亡累积发生率23%(95%CI 14-34),复发累积发生率31%(95%CI 17-47)。
  • 脾大≥22cm或既往脾切除与复发增加相关(HR 6.37,95%CI 2.02-20.1,P=0.002)。
  • 骨髓移植物与复发增加相关(HR 4.92,95%CI 1.68-14.4,P=0.004)。
  • 3个月急性GVHD 3-4级累积发生率10%,广泛型慢性GVHD累积发生率8%;94%患者实现中性粒细胞植入,中位20天(范围14-70)。

临床怎么用

  • 对于骨髓纤维化患者,单倍体移植联合PTCy可作为可行的移植选择。
  • 脾大≥22cm或既往脾切除的患者应警惕复发风险增高。
  • 选择移植物时,骨髓移植物可能与更高复发风险相关,需个体化评估。

局限性

  • 回顾性研究设计,样本量较小(69例),可能存在选择偏倚。
  • 中位随访时间较短(23.1个月),长期结局需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report the results from a multicenter retrospective study of 69 adult patients who underwent haploidentical blood or marrow transplantation (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) for chronic phase myelofibrosis. The median age at BMT was 63 years (range, 41-74). Conditioning regimens were reduced intensity in 54% and nonmyeloablative in 39%. Peripheral blood grafts were used in 86%. The median follow-up was 23.1 months (range, 1.6-75.7). At 3 years, the overall survival, relapse-free survival (RFS), and graft-versus-host-disease (GVHD)-free-RFS were 72% (95% CI 59-81), 44% (95% CI 29-59), and 30% (95% CI 17-43). Cumulative incidences of non-relapse mortality and relapse were 23% (95% CI 14-34) and 31% (95% CI 17-47) at 3 years. Spleen size ≥22 cm or prior splenectomy (HR 6.37, 95% CI 2.02-20.1, P = 0.002), and bone marrow grafts (HR 4.92, 95% CI 1.68-14.4, P = 0.004) were associated with increased incidence of relapse. Cumulative incidence of acute GVHD grade 3-4 was 10% at 3 months and extensive chronic GVHD was 8%. Neutrophil engraftment was reported in 94% patients, at a median of 20 days (range, 14-70). In conclusion, haplo-BMT with PTCy is feasible in patients with myelofibrosis. Splenomegaly ≥22 cm and bone marrow grafts were associated with a higher incidence of relapse in this study.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kunte S, Rybicki L, Viswabandya A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2021. PMID: 34663912. doi:10.1038/s41375-021-01449-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。